792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study

Volume: 70
Published: Jun 1, 2021
Abstract
In the EMPA-REG OUTCOME trial empagliflozin (EMPA) reduced the risk of cardiovascular death, all-cause mortality, and hospitalization for heart failure in patients with type 2 diabetes (T2D) and established cardiovascular disease. The comparative safety of EMPA in routine care is yet to be established. EMPRISE studies the effectiveness, safety and healthcare utilization of EMPA, based on data from Medicare and 2 U.S. commercial claims datasets...
Paper Details
Title
792-P: Comparative Safety of Empagliflozin in Routine Care Patients: Interim Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Published Date
Jun 1, 2021
Journal
Volume
70
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.